Open AccessA one dose experimental cholera vaccine
Author(s) -
Muse Meghan,
Grandjean Cyrille,
Wade Terri K.,
Wade William F.
Publication year - 2012
Publication title -
fems immunology & medical microbiology
Language(s) - English
Resource type - Journals
eISSN - 1574-695X
pISSN - 0928-8244
DOI - 10.1111/j.1574-695x.2012.00993.x
Subject(s) - cholera toxin , immunity , vibrio cholerae , biology , cholera vaccine , cholera , microbiology and biotechnology , antigen , adjuvant , antibody , virology , antibody titer , antiserum , vaccination , immune system , immunology , titer , bacteria , genetics
The number of cholera vaccine doses required for immunity is a constraint during epidemic cholera. Protective immunity following one dose of multiple V ibrio cholerae ( V c) colonization factors ( I naba LPS E l T or, T cp A , T cp F , and CBP ‐ A ) has not been directly tested even though individual V c colonization factors are the protective antigens. Inaba LPS consistently induced vibriocidal and protective antibodies at low doses. A LPS booster, regardless of dose, induced highly protective secondary sera. V c protein immunogens emulsified in adjuvant were variably immunogenic. CBP ‐ A was proficient at inducing high I g G serum titers compared with T cp A or T cp F . After one immunization, T cp A or T cp F antisera protected only when the toxin co‐regulated pilus operon of the challenge V c was induced by AKI culture conditions. CBP ‐ A was not consistently able to induce protection independent of the challenge V c culture conditions. These results reveal the need to understand how best to leverage the ‘right’ V c immunogens to obtain durable immunity after one dose of a cholera subunit vaccine. The dominance of the protective anti‐ LPS antibody response over other V c antigen antibody response needs to be controlled to find other protective antigens that can add to anti‐ LPS antibody‐based immunity.